@article{ref1,
title="Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion",
journal="Journal of psychopharmacology",
year="2023",
author="Lin, Wei-Chen and Su, Tung-Ping and Li, Cheng-Ta and Wu, Hui-Ju and Tsai, Shih-Jen and Bai, Ya-Mei and Tu, Pei-Chi and Chen, Mu-Hong",
volume="37",
number="8",
pages="795-801",
abstract="BACKGROUND: Whether pretreatment working memory and response inhibition function are associated with the rapid and sustained antisuicidal effect of low-dose ketamine among patients with treatment-resistant depression (TRD) and strong suicidal ideation is unclear.  METHODS: We enrolled 65 patients with TRD, comprising 33 who received a single infusion of 0.5 mg/kg ketamine and 32 who received a placebo infusion. The participants performed working memory and go/no-go tasks prior to infusion. We assessed suicidal symptoms at baseline and on postinfusion Days 2, 3, 5, and 7.  RESULTS: The full remission of suicidal symptoms persisted for 3 days after a single ketamine infusion and the ketamine-related antisuicidal effect persisted for 1 week. Lower cognitive impairment at baseline (indicated by a higher rate of correct responses on a working memory task) was associated with the rapid and sustained antisuicidal effect of low-dose ketamine in patients with TRD and strong suicidal ideation.  DISCUSSION: Patients with TRD and strong suicidal ideation but low cognitive impairment may benefit the most from the antisuicidal effect of low-dose ketamine.<p /> <p>Language: en</p>",
language="en",
issn="0269-8811",
doi="10.1177/02698811231182107",
url="http://dx.doi.org/10.1177/02698811231182107"
}